nach oben

International Journal of Clinical Oncology

Erschienen in:

30.03.2020 | Original Article

Prophylactic efficacy of ninjin’yoeito for oxaliplatin-induced cumulative peripheral neuropathy in patients with colorectal cancer receiving postoperative adjuvant chemotherapy: a randomized, open-label, phase 2 trial (HOPE-2)

verfasst von: Yoshiharu Motoo, Yasuto Tomita, Hideto Fujita

Erschienen in: International Journal of Clinical Oncology | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Peripheral neuropathy (PN) is an intractable side effect of oxaliplatin, with no effective prophylaxis so far. Ninjin’yoeito (NYT), a Kampo medicine, is protective against oxaliplatin-induced neuronal cell injury in vitro and ameliorates oxaliplatin-induced PN in vivo. Thus, this randomized controlled trial was aimed at clarifying NYT’s prophylactic effect for oxaliplatin-induced cumulative PN.

Methods

52 patients with colorectal cancers of pathological stage 3 received postoperative adjuvant chemotherapy with the CapeOX regimen: eight cycles of capecitabine (2400 mg/m²) plus oxaliplatin (130 mg/m²) at 3-week intervals. They were randomly assigned to NYT administration and non-administration groups. NYT (9.0 g/day) was administered from day 1 of cycle 1 in the NYT group. The NYT was administered orally daily throughout each cycle. The primary endpoint was the grade of cumulative PN at the end of eight cycles. The secondary endpoints included relative dose intensity (RDI) of oxaliplatin, recurrence-free survival (RFS), and overall survival (OS).

Results

40 patients (n = 20 in both groups) completed 8 chemotherapy cycles. The incidence of grade 2 or greater cumulative PN at the 8th chemotherapy cycle was significantly lower in the NYT group (2/20, 10.0%) than in the control group (11/20, 55.0%, P < 0.01). RDI of oxaliplatin was significantly higher in the NYT group than in the control group (P = 0.02). RFS and OS were better in the NYT group than in the control group, but the difference was not significant.

Conclusions

NYT may reduce the incidence of oxaliplatin-induced cumulative PN and facilitate maintenance of the CapeOX dosing regimen.

Griffith KA, Zhu S, Johantgen M et al (2017) Oxaliplatin-induced peripheral neuropathy and identification of unique severity groups in colorectal cancer. J Pain Symptom Manage 54:701–706CrossRefPubMedPubMedCentral

Nishina T, Kato T, Yamazaki K et al (2015) A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer. Cancer Chemother Pharmacol 76:547–553CrossRefPubMed

Motoo Y, Seki T, Tsutani K (2011) Traditional Japanese medicine, Kampo: its history and current status. Chin J Integr Med 17:85–87CrossRefPubMed

Motoo Y, Hakamatsuka T, Kawahara N et al (2017) Standards of Reporting Kampo Products (STORK) in research articles. J Integr Med 15:182–185CrossRefPubMed

Nishioka M, Shimada M, Kurita N et al (2011) The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen. Int J Clin Oncol 16:322–327CrossRefPubMed

Kono T, Hata T, Morita S et al (2013) Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy. Cancer Chemother Pharmacol 72:1283–1290CrossRefPubMedPubMedCentral

Oki E, Emi Y, Kojima H et al (2015) Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study. Int J Clin Oncol 20:767–775CrossRefPubMed

Hoshino N, Ganeko R, Hida K et al (2018) Goshajinkigan for reducing chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Int J Clin Oncol 23:434–442CrossRefPubMed

Kuriyama A, Endo K (2018) Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Support Care Cancer 26:1051–1059CrossRefPubMed

10.

Motoo Y, Mouri H, Ohtsubo K et al (2005) Herbal medicine Ninjinyoeito ameliorates ribavirin-induced anemia in chronic hepatitis C: a randomized controlled trial. World J Gastroenterol 11:4013–4017CrossRefPubMedPubMedCentral

11.

Miyano K, Nonaka M, Uzu M et al (2018) (2018) Multifunctional actions of ninjinyoeito, a Japanese Kampo medicine: accumulated scientific evidence based on experiments with cells and animal models, and clinical studies. Front Nutr 5:93. https://doi.org/10.3389/fnut.2018.00093.eCollection CrossRefPubMedPubMedCentral

12.

Suzuki T, Yamamoto A, Ohsawa M et al (2015) Ninjin'yoeito and ginseng extract prevent oxaliplatin-induced neurodegeneration in PC12 cells. J Nat Med 69:531–537CrossRefPubMed

13.

Suzuki T, Yamamoto A, Ohsawa M et al (2017) Effect of ninjin'yoeito and ginseng extracts on oxaliplatin-induced neuropathies in mice. J Nat Med 71:757–764CrossRefPubMed

14.

Danno K, Hata T, Tamai K et al (2017) Interim analysis of a phase II trial evaluating the safety and efficacy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer. Cancer Chemother Pharmacol 80:777–785CrossRefPubMed

15.

Mandrekar SJ, Sargent DJ (2010) Randomized phase II trials: time for a new era in clinical trial design. J Thorac Oncol 5:932–934CrossRefPubMedPubMedCentral

16.

Schmoll HJ, Tabernero J, Maroun J et al (2015) Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial. J Clin Oncol 33(32):3733–3740CrossRefPubMed

17.

de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947CrossRefPubMed

18.

Goldberg RM, Gill S (2004) Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer. Cancer Chemother Pharmacol 54:S57–64CrossRefPubMed

19.

Kaku H, Kumagai S, Onoue H et al (2012) Objective evaluation of the alleviating effects of goshajinkigan on PN induced by paclitaxel/carboplatin therapy: a multicenter collaborative study. Exp Ther Med 3:60–65CrossRefPubMed

20.

Abe H, Kawai Y, Mori T et al (2013) The Kampo medicine goshajinkigan prevents neuropathy in breast cancer patients treated with docetaxel. Asian Pac J Cancer Prev 14:6351–6356CrossRefPubMed

21.

Seiwa C, Yamamoto M, Tanaka K et al (2007) Restoration of FcRgamma/Fyn signaling repairs central nervous system demyelination. J Neurosci Res 85:954–966CrossRefPubMed

22.

González-Burgos E, Fernandez-Moriano C, Gómez-Serranillos MP (2015) Potential neuroprotective activity of Ginseng in Parkinson's disease: a review. J Neuroimmune Pharmacol 10:14–29CrossRefPubMed

23.

Sato N, Seiwa C, Uruse M et al (2011) Administration of chinpi, a component of the herbal medicine ninjin-youei-to, reverses age-induced demyelination. Evid Based Complement Alternat Med 2011:617438CrossRefPubMedPubMedCentral

Titel: Prophylactic efficacy of ninjin’yoeito for oxaliplatin-induced cumulative peripheral neuropathy in patients with colorectal cancer receiving postoperative adjuvant chemotherapy: a randomized, open-label, phase 2 trial (HOPE-2)
verfasst von: Yoshiharu Motoo
Yasuto Tomita
Hideto Fujita
Publikationsdatum: 30.03.2020
Verlag: Springer Singapore
Erschienen in: International Journal of Clinical Oncology / Ausgabe 6/2020
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-020-01648-3

Springer Medizin

Prophylactic efficacy of ninjin’yoeito for oxaliplatin-induced cumulative peripheral neuropathy in patients with colorectal cancer receiving postoperative adjuvant chemotherapy: a randomized, open-label, phase 2 trial (HOPE-2)

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2020

Efficacy of neoadjuvant and adjuvant chemotherapy for localized and locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis

SAMD14 promoter methylation is strongly associated with gene expression and poor prognosis in gastric cancer

Salivary metabolites to detect patients with cancer: a systematic review

Fertility preservation and fulfillment of parenthood after treatment of hematological malignancies: results from the ‘Aftercare in Blood Cancer Survivors’ (ABC) study

Clinical outcomes of repeat partial nephrectomy compared to initial partial nephrectomy of a solitary kidney

Clinical impact of revisions to the WHO classification of diffuse gliomas and associated future problems

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie